Arctic Asset Management is an independent Nordic Investment Manager, specialising in Nordic Equities, Nordic Fixed Income and Global Life Science.
We aim to create long-term value for our clients by carefully evaluating risk and reward in the markets.
You don't need to be wealthy to start investing. As an online client, a sum of NOK 1,000 is enough to take the first step towards reaching your long-term financial goal.
Through our Online Investment Platform, anyone can invest in the Arctic funds. The portfolios are actively managed by our experienced investment teams.
We offer advisory service to investment companies and institutional clients looking to invest in the Arctic funds.
We provide discretionary portfolio management for larger institutions and family offices.
This morning, Ulrica Slåne Bjerke, portfolio manager and CIO for our healthcare funds Arctic Aurora LifeScience and Biotech Select, was invited to Dagens Industri’s TV Börsmorgon. She commented on topics currently in focus regarding the sector, obesity stocks Novo and Lilly, falling interest rates positive for biotech, Novavax share price soaring as well as some Swedish med tech companies having an uphill day.
I studio har Albert Collett fått besøk av aksjeforvalter, Alexander Larstedt Lager, og renteforvalter, Vegard Kjølhamar som forteller hvilken informasjon de vektlegger og hvordan de bruker denne inn i investeringsbeslutningene.
Oslo Børs var sterkeste aksjemarked i Norden i april hjulpet av oppgang i råvarepriser, god fart i shipping og en svakere krone. Den nordiske Vinx-indeksen (i NOK) leverte også positiv avkastning. Amerikanske S&P 500 og verdensindeksen falt tilbake med motvind i økte amerikanske langrenter. Flere av de store amerikanske tech-selskapene leverte Q1-resultater bedre enn konsensus forventning og har dermed drevet mye av kursoppgangen mot slutten av måneden.
Both Novo Nordisk and Eli Lilly have reported quarterly results in recent days and continue to show growth rates well above their peers in the pharmaceutical industry.
I denne episoden av Arctic Midt i Måneden er aksjeforvalter Ole Dahl og analytiker Arild Huitfeldt på besøk i studio hos Albert Collett, der de gir innblikk i hvordan de jobber for å oppnå best mulig avkastning for investorene.
On Tuesday April 16, psychiatry specialists, and Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding, Intra-Cellular Therapies rallied nearly 25% on positive Phase 3 clinical trial depression results. The news adds to the list of good news in the treatment landscape for Major Depressive Disorder or MDD, colloquially known as depression.
"Arctic Midt i Måneden" is our mid-month podcast hosted by our CIO, Albert Collett. He invites fund managers and other selected guests to discuss market events, industries and sectors, and investment strategies - among other topics.
Would you like to sign up for our newsletter?